Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SAN711 in Healthy Participants
NCT04971135Phase 1Unknown
- Sponsor
- Saniona
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAN711 in neuropathic pain (4 arms), sponsored by Saniona. Primary endpoints: Treatment-emergent Adverse Events and Adverse Events of Special Interest. Status: unknown.
02
Drugs
SAN711
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT04971135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971135.